Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 4Non-metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Hormone-sensitive Prostate Cancer 2Male Urogenital Diseases 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Non-Metastatic 1Non-metastatic Prostate Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1High-Risk Localized Prostate Cancer 1Healthy Volunteers 1Genital Diseases, Male 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

darolutamide 1Rosuvastatin Calcium 1Magnetic Iron Oxide Nanoparticles 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Healthy Volunteers × darolutamide × Clear all
NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Bayer

Phase 1 Completed
30 enrolled

Healthy Volunteers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡